Significant Pending Applications With Fourth-Quarter User Fee Goals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Significant Pending Applications With Fourth-Quarter User Fee Goals
You may also be interested in...
CDER 2005 NME Approvals: Glass Half Full At Third Quarter Mark?
FDA’s drug review center has approved just over half as many new molecular entities in the first three quarters of 2005 as it approved in the same time period of the preceding year.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011